Invokamet XR (Canagliflozin/Metformin HCl) Patent Expiration, LOE Window & CMS Spending
Invokamet XR (Canagliflozin/Metformin HCl) by Johnson & Johnson: FDA Orange Book core substance LOE 2029-08-26, 0 AB generics, $11.3M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N205879 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2029-08-26 |
| Last Listed Patent or Exclusivity Date | 2029-08-26 |
| Orange Book Patents (*PED Extensions) | 6 patents (3 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $11.3M |
| 2024 Medicare Part D Spend | $10.2M |
| 2024 Medicaid Spend | $1.2M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.